Sponsored By
About this award
The inaugural Informa Pharma Intelligence Awards recognize outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market.
Taking place on 1 September 2022, the Awards brought together leading innovators, to meet and network, discover new opportunities, and reflect on life-changing accomplishments made over the previous year.
Categories cover the entire pharma and biotech lifecycle, including: Pharma Company of the Year, Best New Drug Award, Executive of the Year, Biotech Company of the Year, Best Contract Research Organization, Licensing Deal of the Year and Lifetime Achievement Award.
Key details
Ceremony, Thursday, 01 September, 2022
Palace Hotel, Tokyo
WINNER
CMIC Group
FINALIST
- Avance Clinical
- Calyx
- CMIC Group
- EPS
- ICON
- Parexel
- Syneos Health
WINNER
Daiichi Sankyo
FINALIST
- Daiichi Sankyo
- Shionogi
- Takeda
WINNER
Fujifilm Toyama Chemical, Lutathera for neuroendocrine tumors
FINALISTS
- Astellas’ Padcev (enfortumab vedotin) for urothelial carcinoma
- Fujifilm Toyama Chemical’s Lutathera (lutetium oxodotreotide) for neuroendocrine tumors
- JCR Pharma’s Izcargo (pabinafusp alfa) for mucopolysaccharidosis type II Otsuka Pharm’s Moizerto (difamilast) for atopic dermatitis
- Sanwa Kagaku’s Upasita (upacicalcet sodium hydrate) for secondary hyperparathyroidism in hemodialysis patients
- Takeda’s Alofisel (darvadstrocel) for complex perianal fistulas in Crohn’s disease
- Takeda’s Revestive (teduglutide) for short bowel syndrome
WINNER
PRISM BioLab
FINALISTS
- ARTham Therapeutics
- Chordia Therapeutics
- Cuorips
- Heartseed
- PRISM BioLab
- Rebirthel
- ReboRNA Biosciences
- TMS
WINNER
Sosei Heptares with Neurocrine Biosciences for novel muscarinic receptor agonists
FINALISTS
- Asahi Kasei Pharma with Lilly for chronic pain candidate AK1780
- Heartseed with Novo Nordisk for heart failure candidate HS-001
- Rebirthel with Otsuka Pharmaceutical for iPSC-derived CAR-T/TCR-T therapies
- ReboRNA Biosciences’ research collaboration/option deal with Biogen for CNS disorders
- Sosei Heptares with Neurocrine Biosciences for novel muscarinic receptor agonists
WINNER
Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate)
FINALISTS
- NanoCarrier
- Rakuten Medical (Rakuten Group Inc.’s equity accounted affiliate)
- Sosei Heptares
- Stella Pharma
- StemCell Institute
WINNER
Chris Cargill, executive officer, chief financial officer, Sosei Heptares
FINALISTS
- Chris Cargill, executive officer, chief financial officer, Sosei Heptares (this relates to his position at the time of nomination)
- Hiroshi Kawamoto, director, Rebirthel, and professor, Laboratory of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University
- Tetsuhito Matsuyama, president and CEO, NanoCarrier
- Daisuke Morishita, co-founder and chief scientific officer, Chordia Therapeutics
- Kazuo Nakamura, chairman and CEO, CMIC Group
Dr. Toichi Takenaka
HEADLINE SPONSOR
ICON plc is a world-leading healthcare intelligence and clinical research organisation, with over 38,000 employees in 93 locations in 46 countries around the world, headquartered in Dublin. We advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations. Our services span the entire lifecycle of product development, from molecule to medicine, across a broad range of therapeutic areas. We develop new innovations, drive emerging therapies forward, and improve patient lives.
Avance Clinical offers clinical project management, trial monitoring, regulatory support, safety reporting, scientific and medical writing, data management, statistical and pharmacokinetic services, and external clinical auditing. We operate to the highest standards of compliance required by global regulatory agencies such as the FDA to ensure acceptance of data for drug approvals.
Our clients are international biotech companies in their early phases of drug development that require fast, agile, and adaptive solution-oriented clinical research services. The company uses state-of-the-art technology, gold standard systems, and deep scientific expertise to provide clients with the most successful outcomes.
The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.
